| 0.3676 -0.008 (-2%) | 06-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.48 | 1-year : | 0.58 |
| Resists | First : | 0.41 | Second : | 0.5 |
| Pivot price | 0.36  |
|||
| Supports | First : | 0.28 | Second : | 0.23 |
| MAs | MA(5) : | 0.34 |
MA(20) : | 0.35 |
| MA(100) : | 0.55  |
MA(250) : | 4.8 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 28.1 |
D(3) : | 23.1 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 11.8 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BGM ] has closed above bottom band by 49.1%. Bollinger Bands are 76.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 86 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.39 - 0.39 | 0.39 - 0.39 |
| Low: | 0.32 - 0.32 | 0.32 - 0.32 |
| Close: | 0.37 - 0.37 | 0.37 - 0.38 |
Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.
Fri, 26 Jun 2026
BGM Group(BGM) Stock Options Chain | Quotes & News - Moomoo
Thu, 18 Jun 2026
BGM Group Calls July EGM to Overhaul Share Capital and Governance Structure - The Globe and Mail
Thu, 18 Jun 2026
BGM Group Ltd (BGM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Wed, 17 Jun 2026
BGM Group (BGM) seeks approval for capital reduction and up to 1-for-50 consolidations - Stock Titan
Thu, 11 Jun 2026
12 Health Care Stocks Moving In Thursday's Intraday Session - Adial Pharmaceuticals (NASDAQ:ADIL), Aditxt - Benzinga
Wed, 27 May 2026
BGM - BGM Group Ltd Stock Price and Quote - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 181 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 23.8 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 284 (K) |
| Shares Short P.Month | 36 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.85 |
| Profit Margin | 0 % |
| Operating Margin | -15.7 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 13.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.27 |
| PEG Ratio | 0 |
| Price to Book value | 0.19 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 68% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|